10/21/2005 10685722.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4	AUG 11	STN AnaVist workshops to be held in North America
NEWS 5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS 6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8	OCT 03	MATHDI removed from STN
NEWS 9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10	OCT 06	STN AnaVist workshops to be held in North America
NEWS 11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:44:18 ON 21 OCT 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:44:29 ON 21 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5
DICTIONARY FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10685722.str



chain nodes :
28 29 30 31 32 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
chain bonds :
4-30 8-32 11-28 17-26 20-34 25-28 27-29 30-31 31-32
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-23 13-14 14-15 15-24 16-17 16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
3-4 4-5 4-30 8-32 27-29 31-32
exact bonds :
1-2 1-5 2-3 11-28 17-26 20-34 22-23 22-27 24-25 25-26 25-28 26-27 30-31

normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-23 13-14 14-15 15-24 16-17 16-21 17-18 18-19 19-20 20-21 23-24
isolated ring systems :
containing 1 : 6 : 12 : 16 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:44:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        5 TO ITERATE

100.0% PROCESSED         5 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               3 TO      163

L2             3 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:44:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       93 TO ITERATE

100.0% PROCESSED        93 ITERATIONS                              27 ANSWERS
SEARCH TIME: 00.00.01

L3             27 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10685722a.str
```




```
chain nodes :
28  29  30  31  32  34  36
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23
24  25  26  27
chain bonds :
4-30  8-32  11-28  13-36  17-26  20-34  25-28  27-29  30-31  31-32
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-11  7-8  8-9  9-10  10-11  12-13  12-23  13-14
14-15  15-24  16-17  16-21  17-18  18-19  19-20  20-21  22-23  22-27  23-24  24-25
25-26  26-27
```

exact/norm bonds :
3-4 4-5 4-30 8-32 13-36 27-29 31-32
exact bonds :
1-2 1-5 2-3 11-28 17-26 20-34 22-23 22-27 24-25 25-26 25-28 26-27 30-31

normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-23 13-14 14-15 15-24 16-17 16-21
17-18 18-19 19-20 20-21 23-24
isolated ring systems :
containing 1 : 6 : 12 : 16 :

G1:X,Ak,CH3,CF3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS 36:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 12:46:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 12:46:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L6 7 SEA SSS FUL L4

=> d his

(FILE 'HOME' ENTERED AT 12:44:18 ON 21 OCT 2005)

FILE 'REGISTRY' ENTERED AT 12:44:29 ON 21 OCT 2005
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 27 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 1 S L4
L6 7 S L4 SSS FULL

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 323.52 323.73

FILE 'HCAPLUS' ENTERED AT 12:46:56 ON 21 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 20 Oct 2005 (20051020/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L7 5 L3

=> s l6
L8 2 L6

=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:283488 HCAPLUS
DOCUMENT NUMBER: 142:336252
TITLE: Preparation of benzopyranone derivatives as inhibitors of the release of IL-6 production
INVENTOR(S): Mckie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johannes; Missbach, Martin
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Llc, USA; Novartis Ag
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028472	A1	20050331	WO 2004-US30141	20040913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005137231	A1	20050623	US 2004-942519	20040915
PRIORITY APPLN. INFO.:			US 2003-503295P P	20030915
OTHER SOURCE(S):	MARPAT 142:336252			

GI



I



II

AB Title compds. represented by the formula I. [wherein X, Y = independently H, halo or (halo)alkyl; n = 1-3; R1 = H or Me; R2 = halo, OH, vinyl, CO2H, etc.; and pharmaceutically acceptable salts thereof] were prepared as inhibitors of the release of IL-6 production For example, II was given in a multi-step synthesis starting from the reaction of 3-methoxyphenol with 4-hydroxyphenylacetic acid. I showed inhibition of the release of IL-6 production, MCF-7 breast cancer cell proliferation, and the growth of BG-1 ovarian cancer cells. Thus, I and their pharmaceutical compns. are useful for the treatment or prevention of a bone-resorting disease, a neoplastic disease, arthritis, and etc.

IT **848749-18-8P**, 3-(2,4-Dichlorophenyl)-7-hydroxy-6-methyl-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one **848749-19-9P**,

3-(2,4-Dichlorophenyl)-7-hydroxy-8-methyl-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one **848749-24-6P**,
8-Acetyl-3-(2,4-dichlorophenyl)-7-hydroxy-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyranone derivs. as inhibitors of the release of IL-6 production)

RN 848749-18-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-6-methyl-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 848749-19-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-8-methyl-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 848749-24-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 8-acetyl-3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **848749-23-5P**, 3-(2,4-Dichlorophenyl)-7-hydroxy-8-iodo-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzopyranone derivs. as inhibitors of the release of IL-6

production)
RN 848749-23-5 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-8-iodo-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:392330 HCAPLUS
DOCUMENT NUMBER: 140:391197
TITLE: Preparation of benzopyranone compounds for modulating estrogen receptor expression
INVENTOR(S): Renaud, Johanne; Missbach, Martin; McKie, Jeffrey A.; Bhagwat, Shripad S.
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 125,965.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092572	A1	20040513	US 2003-412997	20030414
US 6620838	B1	20030916	US 2002-125965	20020419
CA 2482986	AA	20031030	CA 2003-2482986	20030418
WO 2003089422	A1	20031030	WO 2003-US12283	20030418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1497277 A1 20050119 EP 2003-733871 20030418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-125965 A2 20020419
US 2003-412997 A 20030414
WO 2003-US12283 W 20030418
OTHER SOURCE(S): MARPAT 140:391197

GI



I



II

AB Benzopyranone compds. of formula I [R = H, acyl, etc.; X = H, halo, CF3; Y = halo, CF3; n = 2-4] are prepared for modulating gene expression in a cell expressing estrogen receptor (ER). The compds. of formula I wherein R is H can be prepared by demethylation of the corresponding phenolic Me ether. The compds. are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chems. or natural hormonal imbalances. Thus, II was prepared from (2-chloro-4-trifluoromethylphenyl)acetic acid, 1-(2-hydroxy-4-methoxyphenyl)-2-(4-hydroxyphenyl)ethan-1-one and 1-(2-chloroethyl)pyrrolidine hydrochloride. The IC50 of II against MCF-7 breast cancer cell was 4.5 nM.

IT **601513-02-4P 601513-06-8P 601513-07-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of benzopyranone compds. for modulating estrogen receptor expression)

RN 601513-02-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-06-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-07-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **601513-35-3P 601513-44-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzopyranone compds. for modulating estrogen receptor expression)

RN 601513-35-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-44-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:354751 HCAPLUS
DOCUMENT NUMBER: 140:350547
TITLE: Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
INVENTOR(S): Friedman, Glenn; McKie, Jeffrey; Wright, Jonathan
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Llc, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035002	A2	20040429	WO 2003-US32932	20031015
WO 2004035002	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004225005	A1	20041111	US 2003-685722	20031014
CA 2502064	AA	20040429	CA 2003-2502064	20031015
EP 1556374	A2	20050727	EP 2003-777639	20031015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015400	A	20050816	BR 2003-15400	20031015

PRIORITY APPLN. INFO.:

US 2002-418469P	P	20021015
US 2003-685722	A	20031014
WO 2003-US32932	W	20031015

OTHER SOURCE(S): MARPAT 140:350547
GI



I

AB This invention relates to benzopyranone compds., compns. comprising a benzopyranone compound and methods for treating or preventing cancer or inhibiting the growth of a cancer cell or neoplastic cell comprising administering an effective amount of a benzopyranone compound The benzopyranone compds. have the formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is halogen, trifluoromethyl or C1-6 alkyl. A

solution of the phenolbenzopyranone (0.74 mmol), triphenylphosphine(1.1 mmol), and 1-(2-hydroxyethyl)pyrrolidine (1.1 mmol) in THF/CH2Cl2 (8 mL) was treated with DIAD (1.1 mmol) and the reaction mixture was stirred at room temperature for about 6 h. The reaction mixture was concentrated and the crude
product was purified using flash chromatog. to provide about 35 mg (10%) of 13-(4-chlorophenyl)-7-fluoro-4- [4-(2-piperidin-1-yl-ethoxy)-benzyl]-chromen-2-one.

IT **681813-32-1P 681813-35-4DP**, derivs.
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzopyranone compds., compns. thereof, and methods for treating or preventing cancer)

RN 681813-32-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-fluoro-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 681813-35-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:855919 HCAPLUS
DOCUMENT NUMBER: 139:350634
TITLE: Preparation of benzopyranone compounds as inhibitors of interleukin-6 release, antitumor agents, etc.
INVENTOR(S): McKie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johanne; Missbach, Martin
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA; Novartis A.-G.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089422	A1	20031030	WO 2003-US12283	20030418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6620838	B1	20030916	US 2002-125965	20020419
US 2004092572	A1	20040513	US 2003-412997	20030414
CA 2482986	AA	20031030	CA 2003-2482986	20030418
EP 1497277	A1	20050119	EP 2003-733871	20030418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-125965 A 20020419
US 2003-412997 A 20030414
WO 2003-US12283 W 20030418

OTHER SOURCE(S): MARPAT 139:350634

GI



I

AB The title compds. I [A = (CH2)n; n = 2 to 4; R1 = H, COR2, etc.; R2 = alkyl, etc.; X = H, halo, etc.; Y = halo, etc.] are prepared I are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chems. or natural hormonal imbalances. Compds. of this invention inhibit both MCF-7 breast cancer and BG-1 ovarian carcinoma cell proliferation; they showed IC50 values of 1.4 nM to 13.6 nM against BG-1 ovarian carcinoma cells and IC50 values of 3 nM to 13.6 nM against MCF-7 breast cancer cells.

IT **601513-02-4P 601513-06-8P 601513-07-9P**
601513-17-1P 601513-18-2P 601513-19-3P
601513-35-3P 601513-44-4P 618885-77-1P
618885-78-2P 618885-79-3P 618885-80-6P
618885-81-7P 618885-82-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyranone compds. as inhibitors of interleukin 6 release, and antitumor agents)

RN 601513-02-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-06-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-07-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-17-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-fluorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-18-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2-bromo-4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-19-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-iodophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-35-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-44-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-77-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-78-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(2,4-dichlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-79-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(4-chloro-2-fluorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-80-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(2-bromo-4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-81-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(4-chloro-2-iodophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-82-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-[4-chloro-2-(trifluoromethyl)phenyl]-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:730534 HCAPLUS
DOCUMENT NUMBER: 139:261167
TITLE: Preparation of benzopyranones for inhibiting interleukin-6
INVENTOR(S): Mckie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johanne; Missbach, Martin
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6620838	B1	20030916	US 2002-125965	20020419
US 2004092572	A1	20040513	US 2003-412997	20030414
CA 2482986	AA	20031030	CA 2003-2482986	20030418
WO 2003089422	A1	20031030	WO 2003-US12283	20030418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1497277	A1	20050119	EP 2003-733871	20030418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
US 2002-125965 A2 20020419
US 2003-412997 A 20030414
WO 2003-US12283 W 20030418

OTHER SOURCE(S): MARPAT 139:261167
GI



I

AB The title benzopyranones [I; n = 2-4; R1 = H, COR2, CO2R2, etc.; R2 = alkyl, aryl, arylalkyl, etc.; X = H, halo, CF3; Y = halo, CF3], useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis and endometriosis, were prepared E.g., a 4-step synthesis of I [n = 2; R1 = H;

X = Cl; Y = CF3] (starting from tert-Bu acetate and 3-chloro-4-iodobenzotrifluoride) which showed IC50 of 0.4 nM against IL-6, was given. The compds. I, wherein R1 = H, can be prepared by demethylation of the corresponding phenolic Me ether. Pharmaceutical composition comprising the compound I was claimed.

IT **601513-02-4P 601513-05-7P 601513-06-8P**
601513-07-9P 601513-17-1P 601513-18-2P
601513-19-3P 601513-20-6P 601513-21-7P
601513-22-8P 601513-23-9P 601513-24-0P
601513-25-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyranones for inhibiting interleukin-6)

RN 601513-02-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-05-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 601513-06-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-07-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-17-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-fluorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-18-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2-bromo-4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-19-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-iodophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-20-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-21-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2,4-dichlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-22-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-fluorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-23-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2-bromo-4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-24-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-iodophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-25-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-[4-chloro-2-(trifluoromethyl)phenyl]-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **601513-35-3P 601513-44-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzopyranones for inhibiting interleukin-6)
RN 601513-35-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-methoxy-4-

[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-44-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l8 ibib abs hitstr tot

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:354751 HCAPLUS
DOCUMENT NUMBER: 140:350547
TITLE: Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
INVENTOR(S): Friedman, Glenn; McKie, Jeffrey; Wright, Jonathan
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Llc, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035002	A2	20040429	WO 2003-US32932	20031015
WO 2004035002	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004225005	A1	20041111	US 2003-685722	20031014
CA 2502064	AA	20040429	CA 2003-2502064	20031015
EP 1556374	A2	20050727	EP 2003-777639	20031015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015400	A	20050816	BR 2003-15400	20031015

PRIORITY APPLN. INFO.:
US 2002-418469P P 20021015
US 2003-685722 A 20031014
WO 2003-US32932 W 20031015

OTHER SOURCE(S): MARPAT 140:350547
GI



I

AB This invention relates to benzopyranone compds., compns. comprising a benzopyranone compound and methods for treating or preventing cancer or inhibiting the growth of a cancer cell or neoplastic cell comprising

administering an effective amount of a benzopyranone compound The benzopyranone compds. have the formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is halogen, trifluoromethyl or C1-6 alkyl. A solution of the phenolbenzopyranone (0.74 mmol), triphenylphosphine(1.1 mmol), and 1-(2-hydroxyethyl)pyrrolidine (1.1 mmol) in THF/CH2Cl2 (8 mL) was treated with DIAD (1.1 mmol) and the reaction mixture was stirred at room temperature for about 6 h. The reaction mixture was concentrated and the crude product was purified using flash chromatog. to provide about 35 mg (10%) of 13-(4-chlorophenyl)-7-fluoro-4- [4-(2-piperidin-1-yl-ethoxy)-benzyl]-chromen-2-one.

IT **681813-32-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzopyranone compds., compns. thereof, and methods for treating or preventing cancer)

RN 681813-32-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-fluoro-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:730534 HCAPLUS

DOCUMENT NUMBER: 139:261167

TITLE: Preparation of benzopyranones for inhibiting interleukin-6

INVENTOR(S): Mckie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johanne; Missbach, Martin

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA

SOURCE: U.S., 21 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6620838	B1	20030916	US 2002-125965	20020419
US 2004092572	A1	20040513	US 2003-412997	20030414
CA 2482986	AA	20031030	CA 2003-2482986	20030418
WO 2003089422	A1	20031030	WO 2003-US12283	20030418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1497277	A1	20050119	EP 2003-733871	20030418

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-125965	A2	20020419
	US 2003-412997	A	20030414
	WO 2003-US12283	W	20030418

OTHER SOURCE(S): MARPAT 139:261167
GI



I

AB The title benzopyranones [I; n = 2-4; R1 = H, COR2, CO2R2, etc.; R2 = alkyl, aryl, arylalkyl, etc.; X = H, halo, CF3; Y = halo, CF3], useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis and endometriosis, were prepared E.g., a 4-step synthesis of I [n = 2; R1 = H; X = Cl; Y = CF3] (starting from tert-Bu acetate and 3-chloro-4-iodobenzotrifluoride) which showed IC50 of 0.4 nM against IL-6, was given. The compds. I, wherein R1 = H, can be prepared by demethylation of the corresponding phenolic Me ether. Pharmaceutical composition comprising the compound I was claimed.

IT **601513-20-6P 601513-21-7P 601513-22-8P**
601513-23-9P 601513-24-0P 601513-25-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyranones for inhibiting interleukin-6)

RN 601513-20-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-21-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2,4-dichlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-22-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-fluorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-23-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2-bromo-4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-24-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-iodophenyl)-4-[[4-[2-(1-

pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-25-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-acetyl-3-[4-chloro-2-(trifluoromethyl)phenyl]-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    44.38     368.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.11      -5.11

STN INTERNATIONAL LOGOFF AT 12:49:07 ON 21 OCT 2005
```